Nerve Growth Factor Inhibitor Study Highlights Promise as an OA Pain Treatment

Ruth Jessen Hickman, MD, is a graduate of the Indiana University School of Medicine. She is a freelance medical and science writer living in Bloomington, Ind.

References

1. Dakin P, DiMartino SJ, Gao H, et al. The efficacy, tolerability and joint safety of fasinumab in osteoarthritis pain: A phase IIb/III double-blind, placebo-controlled, randomized clinical trial. Arthritis Rheumatol. 2019 Nov;71(11):1824–1834. Epub 2019 Sep 20.
2. Miller RE, Malfait AM, Block JA. Current status of nerve growth factor antibodies for the treatment of osteoarthritis pain. Clin Exp Rheumatol. 2017;35 Suppl 107(5):85–87.
3. Miller RE, Block JA, Malfait AM. Nerve growth factor blockade for the management of osteoarthritis pain: What can we learn from clinical trials and preclinical models? Curr Opin Rheumatol. 2017;29(1):110–118.
4. Lane NE, Schnitzer TJ, Birbara CA, et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med. 2010; 363(16):1521–1531.
5. Regeneron Pharmaceuticals. A study to determine the safety and efficacy of fasinumab compared to placebo and naproxen for treatment of adults with pain from osteoarthritis of the knee or hip (FACT OA1) (NCT03161093) . ClinicalTrials.gov. 2020 Sep 11.
6. Regeneron Pharmaceuticals. A study to determine the safety and the efficacy of fasinumab compared to placebo and nonsteroidal anti-inflammatory drugs (NSAIDs) for treatment of adults with pain from osteoarthritis of the knee or hip (FACT OA2) (NCT03304379). ClinicalTrials.gov. 2020 Jan 6.
7. Regeneron Pharmaceuticals. Study to evaluate the effects of fasinumab on peripheral nerve function in patients with pain due to osteoarthritis of the hip or knee. ClinicalTrials.gov. 2020 Apr 22.
8. Staff. Pfizer and Lilly announce tanezumab BLA accepted. ThePharmaLetter. 2020 Feb 2.